Building a pipeline of immuno-infectiology candidates to fight against anti-microbial resistance
Alpioner Therapeutics is a biotech company developing a whole-cell vaccine platform consisting of genetically optimized strains of human pathogens undergoing an attenuation process which delivers a Killed but Metabolically Active (KBMA) vaccine substance. This platform has already generated a first candidate targeting a human multi-resistant pathogen, Pseudomonas aeruginosa. It carries on the potential for further applications against other resistant pathogens.
Alpioner Therapeutics mission is to build a pipeline of immuno-infectiology candidates to fight against anti-microbial resistance (AMR).
Alpioner Therapeutics is a biotechnology company developing the first KBMA vaccine candidate against pseudomonas aeruginosa
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
![]() | Réseau SATT | Other 7 Apr 2024 | | |
![]() | Toulouse Tech Transfer | Other 29 Feb 2024 | | |
![]() | LUTECH | Other 29 Feb 2024 | | |
![]() | SATT Nord | Other 7 Mar 2024 | | |
![]() | SATT Aquitaine Science Transfert | Other 29 Feb 2024 | | |
![]() | SATT AxLR | Other 29 Feb 2024 | | |
![]() CIC Bank, Banking | CIC Bank, Banking | Other 31 Mar 2024 | | |
![]() PULSALYS Research, Research Services | PULSALYS Research, Research Services | Other 29 Feb 2024 | | |
![]() SATT CONECTUS Research, Research Services | SATT CONECTUS Research, Research Services | Other 29 Feb 2024 | | |
![]() Linksium Venture Capital and Private Equity Principals | Linksium Venture Capital and Private Equity Principals | Other 10 Jul 2024 | |